Canaccord Genuity Reiterates Buy Rating on Regeneron Pharma (REGN)
Tweet Send to a Friend
Canaccord Genuity analyst John Newman reiterated a Buy rating and $850.00 price target on Regeneron Pharma (NASDAQ: REGN).The analyst commented ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
